UBS analyst Marc Goodman says Valeant Pharmaceuticals receiving a subpoena after 18 Democratic members of the House Committee on Oversight and Government Reform sent a letter requesting Chairman Jason Chaffetz send one to the company is "far from certain." This is a subpoena request by the minority party, Goodman reminds in a research note titled "A Possible Overreaction to Subpoena Concerns." The Democrats have asked on pricing issues before, and the Chairman has declined, he points out. The analyst expects the stock to "bounce back" following the selloff. Goodman keeps a Buy rating on Valeant after the shares dropped $33.14 yesterday to $166.33. The analyst has a $285 price target for the stock.